Intervention not reported
Satisfaction with the information provided (Single and multi‐component intervention) · People with a health condition or nominally 'well' considering real clinical trial participation (across a range of topic areas)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Anxiety, or other psychological distress (Single and multi‐component intervention) · People with a health condition or nominally 'well' considering real clinical trial participation (across a range of topic areas)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Retention of knowledge (Single and multi‐component intervention) · People with a health condition or nominally 'well' considering real clinical trial participation (across a range of topic areas)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Satisfaction with the decision‐making process (multi‐component intervention) [questionnaire, assessed immediately post‐intervention] · People with a health condition or nominally 'well' considering real clinical trial participation (across a range of topic areas)
1 finding from 1 review
Intervention not reported
Recurrent pericarditis Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers) Intervention: colchicine with NSAID; Comparison: NSAID alone
The intervention probably leads to lower recurrent pericarditis Chest pain + (ECG changes +/‐… (moderate certainty).
1 finding from 1 review
Intervention not reported
Acute pericarditis Chest pain + (ECG changes +/‐ echocardiographic changes +/‐ raised inflammatory markers) Intervention: colchicine with NSAID; Comparison: NSAID alone
The intervention probably leads to lower acute pericarditis Chest pain + (ECG changes +/‐ echocardiographic… (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal macrovascular outcomes 1. Composite a. Intervention vs metformin [1a. 6 months to 4 years] b. Intervention vs thiazolidinediones [1b. 52 weeks to 4 years] c. Intervention vs meglitinide [1c. 12 months to 15 months]2. Non‐fatal myocardial... · participants with type 2 diabetes mellitus
The intervention may leads to lower non‐fatal macrovascular outcomes 1. Composite a. Intervention vs… (low certainty).
1 finding from 1 review
RR 0.67 [0.48, 0.93]
1 study · 3 participants
Low
Intervention not reported
Cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years] b. Intervention vs insulin [6 years to 10 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in cancer a. Intervention vs thiazolidinediones [52 weeks to 4 years]… (low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life a. Intervention vs thiazolidinediones [12 months] b. Intervention vs insulin [6 years] c. Intervention vs alpha‐glucosidase inhibitors [12 months] · participants with type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Adverse events 1. All adverse events 2. Drop‐outs due to adverse events Interventions vs thiazolidinediones [1. 6 months to 12 months] [2. 24 weeks to 52 weeks] · participants with type 2 diabetes mellitus
The intervention may leads to lower adverse events 1. All adverse events 2. Drop‐outs due to adverse… (low certainty).
1 finding from 1 review
RR 0.88 [0.78, 0.99]
1 study · 3 participants
Low
Intervention not reported
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4… (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs meglitinide [d. 12 months to 17 m... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in cardiovascular mortality a. Intervention vs metformin [a. 24 weeks… (low certainty).
1 finding from 1 review
Marginal bone level change · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional triamcinolone changes maximal mouth opening (interincisal distance) compared with intralesional triamcinolone plus salvianolic acid B (very low certainty).
1 finding from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional triamcinolone changes burning sensation (VAS 0-100) compared with intralesional triamcinolone plus salvianolic acid B (very low certainty).
2 findings from 1 review
MD -1.00 [-10.37, 8.37]
1 study · 28 participants
Very low
MD -16.30 [-28.15, -4.45]
1 study · 28 participants
Very low
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Intralesional betamethasone may leads to higher clinical resolution compared with intralesional triamcinolone acetonide (low certainty).
1 finding from 1 review
Clinical score (14 days) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether intralesional betamethasone changes clinical score (14 days) compared with intralesional triamcinolone acetonide (very low certainty).
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Intralesional betamethasone showed no clear difference in pain (mean score) compared with intralesional triamcinolone acetonide (low certainty).
1 finding from 1 review
Disease control · bullous pemphigoid
It is very uncertain whether prednisone plus azathioprine changes disease control (at 6 months) compared with prednisone (very low certainty).
1 finding from 1 review
Mortality (at 6 months) · bullous pemphigoid
It is very uncertain whether prednisone plus azathioprine changes mortality (at 6 months) compared with prednisone (very low certainty).
1 finding from 1 review